Osilodrostat
CLCI699C1201
Phase 2 small_molecule completed
Quick answer
Osilodrostat for Cushing's Syndrome is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Cushing's Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed